NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 2.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 88,544 shares of the company’s stock after acquiring an additional 2,222 shares during the period. Geode Capital Management LLC’s holdings in NewAmsterdam Pharma were worth $2,276,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its position in NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock valued at $102,763,000 after purchasing an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of NewAmsterdam Pharma by 2,410.4% during the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company’s stock valued at $59,499,000 after buying an additional 2,222,900 shares during the last quarter. Alliancebernstein L.P. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $47,752,000. TimesSquare Capital Management LLC grew its holdings in NewAmsterdam Pharma by 250.9% in the 4th quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company’s stock worth $23,016,000 after buying an additional 640,329 shares in the last quarter. Finally, American Century Companies Inc. bought a new position in NewAmsterdam Pharma in the 4th quarter worth approximately $8,907,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 1,135 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares of the company’s stock, valued at $67,775,166.81. This represents a 0.04 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at approximately $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 19.50% of the stock is currently owned by corporate insiders.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $18.55 on Wednesday. The firm has a market cap of $2.04 billion, a PE ratio of -7.13 and a beta of -0.01. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $27.29. The firm has a 50 day simple moving average of $19.57 and a 200 day simple moving average of $21.22.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NAMS. HC Wainwright reiterated a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $42.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank upped their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Thursday, February 27th. Finally, UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.